29,000 Shares in Edwards Lifesciences Corporation $EW Bought by Renaissance Technologies LLC

Key Points

• Renaissance Technologies acquired 29,000 shares of Edwards Lifesciences in the first quarter, valued at approximately $2.32 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly bullish, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards reported quarterly EPS of $0.78 and revenue of $1.74 billion, beating estimates and delivering 13.6% year-over-year revenue growth. The stock opened at $92.01, up 2.6%, while insiders sold roughly $3.69 million in shares over the past three months.

Renaissance Technologies LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 29,000 shares of the medical research company's stock, valued at approximately $2,322,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the fourth quarter worth about $26,000. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $25,000. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,671,117.80. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 43,539 shares of company stock worth $3,685,364 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on EW. Piper Sandler reissued an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. TD Cowen reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. UBS Group started coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Stock Up 2.6%

EW opened at $92.01 on Tuesday. The company has a fifty day moving average of $88.26 and a two-hundred day moving average of $84.14. The stock has a market capitalization of $52.98 billion, a price-to-earnings ratio of 52.88, a PEG ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the company posted $0.67 EPS. The company's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source